CC-92328
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
What's the purpose of the trial?
This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM).
Accepting patients
Participating Centers
There are 6 centers participating in this trial. Enter a location below to find the closet center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- CC-92328
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.